![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Tangen Gets BARDA Funding for an Anthrax Assay
Tangen Gets BARDA Funding for an Anthrax Assay
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
Tangen Biosciences has received a $3.3 million award from the Biomedical Advanced Research and Development Authority (BARDA) to develop an anthrax diagnostic assay.
The BARDA funding will support a clinical trial for a bloodstream-anthrax diagnostic that uses the company’s TangenDx platform.
Tangen said the research on the anthrax diagnostic will be expanded to develop an antimicrobial resistance assay.
Upcoming Events
-
18Jul
-
21Oct